Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2019-08-07 to 2021-06-23
ROUNDS
2
joined, none as lead
ROUNDS JOINED · USD
$68M
across 2 rounds
CO-INVESTORS
9
named beside it
Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2019-08-07 to 2021-06-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2021-06-23 | [ PART ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $33M | 2019-08-07 | [ PART ] |